Page 28 - Read Online

Oiseth et al. Cancer immunotherapy

Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J cancers in a phase I/IIa trial. Presented at: 2017 AACR Annual
Med 2015;372:2521-32. Meeting; April 1-5, 2017; Washington, DC. Abstract CT116. Available
80. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, from: http://www.aacr.org/Documents/AACR2017_ProgramGuide.
Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss pdf#search=CT116. [Last accessed on 30 Oct 2017]
MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon 96. Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M,
RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta
Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP,
MD. Pneumonitis in patients treated with anti-programmed death-1/ Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP.
programmed death ligand 1 therapy. J Clin Oncol 2017;35:709-17. Identification of essential genes for cancer immunotherapy. Nature
81. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes 2017;548:537-42..
A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial 97. Beasley D. The cost of cancer: new drugs show success at a steep
of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med price. Reuters 2017, April 3. Available from: http://www.reuters.com/
2006;355:1018-28. article/usa-healthcare-cancer-costs/rpt-the-cost-of-cancer-new-drugs-
82. Attarwala H. TGN1412: from discovery to disaster. J Young Pharm show-success-at-a-steep-price-idUSL2N1HB06W. [Last accessed on
2010;2:332-6. 30 Oct 2017]
83. Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies 98. Shelley S. Oncology: a new era in therapies; same cost concerns.
targeting the PD-1 signaling pathway. J Biomed Sci 2017;24:26. Pharmaceutical Commerce. 2016, May 31. Available from: http://
84. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, pharmaceuticalcommerce.com/brand-marketing-communications/
Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, oncology-new-era-therapies-cost-concerns/. [Last accessed on 30 Oct
Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell 2017]
NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, 99. FDA News Release. FDA approves first cancer treatment for any solid
Wirth LJ, Dizon DS. Clinical cancer advances 2017: annual report tumor with a specific genetic feature. Available from: https://www.
on progress against cancer from the American Society of Clinical fda.gov/newsevents/newsroom/pressannouncements/ucm560167.
Oncology. J Clin Oncol 2017;35:1341-67. htm. [Last accessed on 30 Oct 2017]
85. Sharma P. Immune checkpoint therapy and the search for predictive 100. Allison JP. Unleashing the immune system to combat cancer. 2015
biomarkers. Cancer J 2016;22:68-72. Lasker-DeBakey Clinical Medical Research Award. Available from:
86. Hegde PS, Karanikas V, Evers S. The where, the when, and the how http://www.laskerfoundation.org/awards/show/unleashing-immune-
of immune monitoring for cancer immunotherapies in the era of system-combat-cancer/. [Last accessed on 30 Oct 2017]
checkpoint inhibition. Clin Cancer Res 2016;22:1865-74. 101. Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of
87. Gajewski TF. The next hurdle in cancer immunotherapy: overcoming murine T-lymphoma defined with monoclonal antibody. J Immunol
the non-T-cell-inflamed tumor microenvironment. Semin Oncol 1982;129:2293-300.
2015;42:663-71. 102. Metchnikoff E. Untersuchungen ueber die mesodermalen phagocyten
88. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. einiger wirbeltiere. Biologisches Centralblatt 1883;3:560-5. (in
Science 2015;348:69-74. German)
89. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel 103. Von Behring E, Kitasato S. Ueber das Zustandekommen der
JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch
AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Med Wschr 1890;16:1113-4. (in German)
Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, 104. Bordet J. Les Leucocytes et les propriétés du sérum ches les vaccinés.
Chan TA. Cancer immunology. Mutational landscape determines Ann de l’Inst Pasteur 1895;ix:462-506. (in French)
sensitivity to PD-1 blockade in non-small cell lung cancer. Science 105. Ehrlich P. Die Wertbesmessung des Diphterieilserums und deren
2015;348:124-8. theoretische Grundlagen. Klinische Jahrbuch 1897;6:299-326. (in
90. Passardi A, Canale M, Valgiusti M, Ulivi P. Immune checkpoints as a German)
target for colorectal cancer treatment. Int J Mol Sci 2017;18:E1324. 106. Landsteiner K. Über Agglutinationserscheinungen normalen
91. Leal AD, Paludo J, Finnes HD, Grothey A. Response to pembrolizumab menschlichen Blutes. Wien Klin Wochenschr 1901;14:1132-34. (in
in patients with mismatch repair deficient (dMMR) colorectal cancer German)
(CRC). J Clin Oncol 2017;35:3558. 107. Jensen CO. Experimental studies on cancer in mice. Zentralblatt fur
92. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Bakteriologie, Parasitenkunde und Infectionskrankheiten 1903;34:28-
Andrews MC, Tetzlaff MT, Lazar A, Hwu P, Hwu W-J, Glitza IC, 34 and 122-143. Translated from German, In: Shimkin MB. Some
Tawbi HA-H, Patel SP, Lee JE, Davies MA, Gershenwald JE, Futreal Classics of Experimental Oncology, 50 Selections, 1775-1965
A, Sharma P, Allison JP, Jenq RR. Association of the diversity and National Institutes of Health (U.S.) Publication No. 80-2150 October
composition of the gut microbiome with responses and survival (PFS) 1980, pp 78-105. Available from: https://babel.hathitrust.org/cgi/pt?id
in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. J =mdp.39015003789719;view=1up;seq=119. [Last accessed on 30 Oct
Clin Oncol 2017;35:3008. 2017]
93. Derosa L, Routy B, Enot D, Baciarello G, Massard C, Loriot Y, 108. Loeb L. Ueber die Enstehung eines Sarkoms nach Transplantation
Fizazi K, Escudier BJ, Zitvogel L, Albiges L. Impact of antibiotics on eines Adenocarcinoms einer japanischen Maus. Zeitschrift für
outcome in patients with metastatic renal cell carcinoma treated with Krebsforschung 1908;7:80-110. (in German)
immune checkpoint inhibitors. J Clin Oncol 2017;35:abstract 462. 109. Little CC. A possible mendelian explanation for a type of inheritance
94. Mbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge apparently non-mendelian in nature. Science 1914;40:904-6.
WH. The role of indoleamine 2, 3-dioxygenase in immune suppression 110. Strong LC. Inbred mice in science. In: Morse HC III (editor) Origins
and autoimmunity. Vaccines (Basel) 2015;3:703-29. of inbred mice. NewYork: Academic Press;1978. p. 45-67.
95. Siu LL. BMS-986205, an optimized indoleamine 2,3-dioxygenase 111. Gorer PA, Lyman S, Snell GD. Studies on the genetic and antigenic
1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamics basis of tumour transplantation: linkage between a histocompatibility
activity, alone and in combination with nivolumab (Nivo) in advanced gene and “fused” in mice. Proc R Soc Lond 1948;135:499-505.
260 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ October 31, 2017